MOUNTAIN VIEW, Calif., June 2, 2025 — AliveCor, the global leader in AI-powered cardiology, today announced a 12-month partnership with British Heart Foundation, — the UK’s leading cardiovascular research charity — to help fund lifesaving research.
The cause-related marketing campaign will see AliveCor donate £3 to British Heart Foundation for every KardiaMobile® 6L device sold in the UK. This financial contribution will directly support the charity's mission to fund pioneering research aimed at diagnosing, treating, and preventing cardiovascular disease.
This collaboration unites two organisations with shared values and a commitment to creating real impact.
AliveCor, renowned for its clinically validated KardiaMobile® ECG devices, empowers individuals to detect heart rhythm irregularities anytime, anywhere. With over 300 million ECGs recorded globally, AliveCor is transforming the way people engage with their heart health—offering a diagnostic , real-time solution outside of traditional healthcare settings.
British Heart Foundation brings over 60 years of expertise in scientific research, funding over £100 million annually to discover new treatments and interventions for cardiovascular disease—still the world’s biggest killer. Its credibility, reach, and legacy in improving public health make it one of the most respected charities in the country.
“We’re proud to support British Heart Foundation in powering groundbreaking research to save and improve lives,’’ said Chris Shelford, Senior Director of Marketing at AliveCor. “Our technology helps people detect some heart issues earlier — and now, every purchase helps fund the research that keeps hearts beating longer.”
“We’re delighted to partner with AliveCor,” said Chloe Embury, Head of Corporate Partnerships at British Heart Foundation. “Together, we’re not only helping people manage their heart health today but driving progress for future generations.”
The campaign runs until May 31st, 2026 and includes marketing, digital campaigns, and in-store messaging across AliveCor’s retail and online channels.
To learn more, visit: KardiaMobile.co.uk
About KardiaMobile®
KardiaMobile® is the first personal ECG to be recommended by NICE for use within the National Health Service (NHS) in England and Wales.[i] KardiaMobile® would be prescribed by a healthcare professional for people experiencing arrhythmia (irregular heart rhythm) symptoms more than 24 hours apart. The instructions for use state that all interpretations of ECG recordings are reviewed by a healthcare professional and used to support clinical decision making.
The user starts a 30-second ECG recording on their smartphone via the Kardia app, by placing two fingers from each hand on each of the two top electrodes - enabling the patient to remotely capture a recording of their heart activity. KardiaMobile® provides instant detection of atrial fibrillation (AF), bradycardia (slow heart rhythm) and tachycardia (fast heart rhythm) which can be indicators of cardiovascular disease.
Once a recording has been taken by KardiaMobile®, the artificial intelligence algorithm performs an automatic analysis and informs the patient whether AF, bradycardia, tachycardia or a normal rhythm is detected. The data collected can be sent directly to a clinician for further analysis and consultation. This allows patients to take positive steps to remotely monitor their own heart health as early diagnosis of AF is essential to avoid the potential consequences of an AF-related stroke.
About AliveCor
AliveCor, Inc., the leading provider of FDA-cleared personal electrocardiogram (ECG) technology, is transforming cardiology with its medical-grade AI solutions. AliveCor is committed to providing innovative devices and services that empower patients and physicians with personalized and actionable heart data. With over 300 million ECGs recorded, the company’s Kardia devices are the most clinically validated personal ECGs in the world and can remotely detect six of the most common heart arrhythmias in just 30 seconds. The Kardia 12L ECG System, the company’s first offering designed exclusively for use by healthcare providers, is powered by KAI 12L to detect 35 cardiac conditions (14 arrhythmias and 21 morphologies). AliveCor's enterprise platform allows third-party providers to manage their patients’ and customers’ heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, addressing gaps in care and improving the treatment experience for patients across a range of disease areas. AliveCor is a privately held company headquartered in Mountain View, Calif. For more information, visit alivecor.com and follow us on LinkedIn, X, Instagram and Facebook.
About the British Heart Foundation
Far too many of us have felt the pain of losing someone we love to cardiovascular disease, the world’s biggest killer. With your support, British Heart Foundation (BHF) powers groundbreaking research to save and improve lives.
Since 1961, your support has helped us fund scientific breakthroughs that are keeping more families together today, from pacemaker technology and portable defibrillators to proving that statins can help save lives. And with your support, our ambitions for the years to come are even bolder.
Every three minutes someone loses their life to cardiovascular disease in the UK. We’re dedicated to powering advances in cardiovascular science and healthcare that will bring us closer to the day that everyone has a healthier heart for longer. But we can’t do it without your support. Together, the next breakthroughs in diagnosing, treating, and preventing cardiovascular disease are in reach.
British Heart Foundation is a registered charity in England and Wales (225971) and in Scotland (SCO39426), and the Isle of Man (1295).
[i] www.nice.org.uk. KardiaMobile for detecting atrial fibrillation. [online] Available at https://www.nice.org.uk/guidance/mtg64/chapter/1-Recommendations. Last accessed: May 2025